For American parents, particularly those with young children, the past couple of months have been dizzying and beyond frustrating.
In early February, federal regulators announced they would evaluate Pfizer-BioNTech’s coronavirus vaccine for the youngest children — only to scrap that plan 10 days later, citing doubts about the vaccine’s effectiveness in that age group.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.